Schedule 13G ownership disclosure

C4 Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 12529R107

Event date: 2025-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • OrbiMed Advisors LLC

    Shares: 1,666,800.00 · Class: 2.3%

  • OrbiMed Capital LLC

    Shares: 3,568,346.00 · Class: 5.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000947871-25-001020
Form type
SCHEDULE 13G/A
Filer
C4 Therapeutics, Inc.
CIK
CIK 1662579
Filed
Nov 14, 2025
Reporting period
Sep 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub